Aldeyra Therapeutics (ALDX) to Release Earnings on Friday

Aldeyra Therapeutics (NASDAQ:ALDX) is expected to be releasing its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $24.25 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:00 PM ET.

Aldeyra Therapeutics Price Performance

Shares of Aldeyra Therapeutics stock opened at $5.21 on Wednesday. The business has a 50-day simple moving average of $5.01 and a 200 day simple moving average of $5.17. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20. The firm has a market capitalization of $313.43 million, a price-to-earnings ratio of -7.14 and a beta of 0.98.

Wall Street Analyst Weigh In

Separately, BTIG Research restated a “buy” rating and set a $9.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aldeyra Therapeutics presently has an average rating of “Hold” and an average target price of $9.50.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several institutional investors have recently bought and sold shares of ALDX. AQR Capital Management LLC lifted its stake in Aldeyra Therapeutics by 456.3% during the 1st quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock valued at $2,257,000 after acquiring an additional 321,992 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Aldeyra Therapeutics during the first quarter valued at about $218,000. Jane Street Group LLC purchased a new position in Aldeyra Therapeutics during the first quarter worth about $1,024,000. Acadian Asset Management LLC grew its position in Aldeyra Therapeutics by 7,402.7% in the 1st quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company’s stock worth $551,000 after purchasing an additional 94,681 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Aldeyra Therapeutics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 8,769 shares during the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.